Measurement of a novel serological marker for pancreatic cancer in esophageal, gastric, hepatic, bile duct and colorectal cancers

Measurement of a novel serological marker for pancreatic cancer in esophageal, gastric, hepatic, bile duct and colorectal cancers - A specific diagnostic marker for pancreatic cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027906

Enrollment

100

Registered

2017-06-23

Start date

2017-05-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esohageal cancer, gastric cancer, hapatic cancer, bile duct cancer, colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) more than 20 years old and less than 90 years old (2) patients of esophageal, gastric, hepatic, bile duct and colorectal cancers newly diagnosed and previously untreated (3) all individuals classified as controls are diagnosed as chronic hepatitis or gastrointestinal diseases with being evaluated for non-pancreatic diseases.

Exclusion criteria

Exclusion criteria: (1) patients who were suffering from any kind of malignancies (2) sever renal or liver dysfunction (3) individuals who did not accept informed consent (4) unsuitable individuals for this clinical study

Design outcomes

Primary

Measure	Time frame
Comparison of the IGFP levels between patients of Esohageal, gastric, hapatic, bile duct, colorectal cancers and control individuals	—

Secondary

Measure	Time frame
Comparison of the area under the curve (AUC) of Reciever Operating Characteristic Curves (ROC curves) between IGFP and CA19-9	—

Countries

Japan

Contacts

Public ContactKeisuke Taniuchi

Kochi Medical School Hospital, Kochi University Department of Gastroenterology and Hepatology

ktaniuchi@kochi-u.ac.jp088-880-2339

Outcome results